AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03208166 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual Care
Description: Standard medical care
Study NCT03208166 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Usual Care
Description: Standard medical care
Study NCT03315000 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Same as placebo arm description
Study NCT03332862 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: catheter ablation
Description: catheter ablation for atrial fibrillation treatment
Study NCT03332862 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: catheter ablation
Description: catheter ablation for atrial fibrillation treatment
Study NCT03456908 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: 18F-TFB-PET
Description: Infusion of F-18 TFB and PET / CT imaging
Study NCT03353935 — intervention group
Intervention type: OTHER
Intervention: Validated questionnaires
Description: Patients were administered pre- and post-operatively the three validated questionnaires ((FSFI, ICIQ-UI short form Italian, NBD score) investigating sexual, urinary, and fecal function, respectively.
Study NCT00493688 — intervention group
Intervention type: OTHER
Intervention: Cardiopulmonary Exercise Testing (CPET)
Description: Pedaling on a Stationary Bicycle at 60 Revolutions Per Minute as the Resistance to Pedaling Gradually Increases.
Study NCT03150173 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Onsite treatment
Description: Participants will see a buprenorphine treatment provider who will assess for clinical criteria for opioid use disorder and write a prescription for buprenorphine treatment, which will be filled in a community pharmacy.
Study NCT03150173 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced referral
Description: Participants will receive an expedited appointment at a community health center for evaluation for buprenorphine treatment
Study NCT03150173 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Buprenorphine
Description: all participants will receive buprenorphine
Study NCT03150173 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buprenorphine
Description: all participants will receive buprenorphine
Study NCT04458610 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Given IV
Study NCT04458610 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zanubrutinib
Description: Given PO
Study NCT03841357 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abatacept Injection
Description: Supplied as a weekly injection via a pre-filled syringe
Study NCT03841357 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual Care
Description: Usual care will be defined by the clinical management team but includes steroid joint injections and non- steroidal anti-inflammatory drugs
Study NCT03841357 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Usual care will be defined by the clinical management team but includes steroid joint injections and non- steroidal anti-inflammatory drugs
Study NCT01484730 — intervention group
Intervention type: DEVICE
Intervention: Multi-Spectral and Laser Speckle Imaging
Description: Changes in skin tissue and blood flow.
Study NCT02388386 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PROTEUS-SENSOR
Description: An edible sensor system, Proteus Digital™ has been developed for electronically confirming medication adherence, gathering physiologic metrics and communicating these data to patients. The system consists of two major components: an edible sensor and a wearable receiver health monitor. An electrical signal is activated upon ingestion of the Proteus Digital micro-sensor with transmission of this signal to a receiving abdominal patch to quantify medication compliance.
Study NCT04349124 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Nifedipine Extended-Release Tablets
Description: Antihypertensive
Study NCT01007851 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: triptorelin acetate
Description: single dose of 0.1 mg triptorelin subcutaneous injection on the 3rd day after embryo transfer
Study NCT01007851 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: NaCl %0.9
Description: 0.1 ml sterile saline sc injection 3 days after embryo transfer
Study NCT00432445 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Proton Beam Radiation Therapy
Description: Radiation given daily for 5 days in a row each week (except for Saturdays, Sundays, and holidays). The whole treatment will take about 4-6 weeks.
Study NCT00432445 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ophthalmic EUA
Description: Ophthalmic examination under anesthesia including dilated eye exam, ocular fundus photography (Ret-Cam), ocular echography and neuro-radiologic assessment (as deemed necessary)
Study NCT02241642 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VIVASURE CLOSURE DEVICE™
Description: Large hole vascular closure device
Study NCT00005908 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel - Dose A
Description: Dose A-Cohort 1 Docetaxel 75 mg/m\^2 intravenous day 1
Study NCT00005908 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anastrozole
Description: 1 mg orally daily for five years
Study NCT00005908 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: 600 mg/m\^2 will be diluted in 100 mL 0.9% normal saline (NS) and administered intravenously over 30 minutes on day 1
Study NCT00005908 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel - Dose B
Description: Dose B - Cohort 2 Docetaxel 60 mg/m\^2 intravenous day 1
Study NCT00005908 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin hydrochloride
Description: 60 mg/m\^2 will be administered as a slow intravenous push on day 1
Study NCT00005908 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamoxifen Citrate
Description: 20 mg/day orally for five years
Study NCT00005908 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine - Dose B
Description: Dose B - Cohort 2 capecitabine 937.5 mg/m\^2 orally twice daily day 2-15
Study NCT00005908 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine - Dose A
Description: capecitabine 1000 mg/m\^2 orally twice daily day 2-15 for 4 cycles
Study NCT00475436 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK573719
Study NCT03003923 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Taste exposure
Description: Exposure to the same vegetable
Study NCT03003923 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutritional education
Description: Eat Well and Strive for Five nutritional education
Study NCT02831439 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Basic public reporting
Description: The basic intervention will comprise public reporting through the WCHQ website. Individual-level, claims data submitted for billing to third party payers by participating healthsystems will be used to (i) identify cohorts of women with incident breast cancer at the practice-level and (ii) construct the metrics for public reporting and individual benchmarking information. These data are consistent with Medicare and Marketscan claims in both format and content thereby ensuring seamless application of the validated algorithm as well as construction of outcome variables as proposed in Aims 1 and 2 of the study.
Study NCT02831439 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced intervention
Description: The enhanced intervention adds an app comprising a decision tool, patient education and communication information that will be delivering concise, readily accessible information about the main components of the intervention. Specifically, physicians in participating practices will be provided a smartphone-based, point-of-care application that will include i) a list of the unproven/ineffective interventions with statements about a) scientifically proven appropriate use; b) proven or suspected downsides to inappropriate use; ii) clinical calculators that allow physician to input individual patients' clinical/tumor characteristics for each test; iii) practice-specific summary of publicly reported results; and iv) printable patient information adapted from the ASCO Choosing Wisely website.
Study NCT02831439 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Control group - observational
Description: Comparison states will be used to evaluate the interventions in light of possible secular trends in the region and the nation. The design strategy will enable estimates of the effectiveness of the basic intervention (Aim 1) by comparing (i) the pre-intervention rates to post-intervention rates as well as by comparing (ii) changes between the pre- and post-intervention periods for the treatment state (WI) relative to comparison states, neighboring states and others. A similar approach will be used in Part II to provide estimates of the enhanced intervention's impact relative to the basic intervention and contemporary usual care provided in control states, thereby enabling the cost-savings analyses proposed as part of Aim 3.
Study NCT01264484 — intervention group
Intervention type: DEVICE
Intervention: Advantage Prosthetic Heart Valve
Description: All patients eligible for this study are treated with an Advantage prosthetic heart valve
Study NCT03268226 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Beclometasone dipropionate/Formoterol Fumarate/Glycopyrronium
Description: An inhaled dose of CHF 5993 pMDI 100+6+12.5 μg twice a day (Total daily dose: BDP 400 μg / FF 24 μg / GB 50 μg)
Study NCT03386591 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naloxone
Description: Comparing pharmacokinetics of naloxone
Study NCT03386591 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mucosal atomization device and syringe
Description: Injection
Study NCT03386591 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Narcan
Description: Nasal Spray
Study NCT03386591 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intramuscular Auto Injector
Description: Intramuscular injection
Study NCT00501410 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-FU
Description: 2400 mg/m\^2 by vein over 46 Hours On Days 1 \& 2.
Study NCT00501410 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Initial Dose = 400 mg/m\^2 by vein, then 250 mg/m\^2 Weekly On Days 1 \& 8
Study NCT00501410 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Description: Starting dose level: 100 mg by mouth daily on days 1-14.
Study NCT00501410 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: 400 mg/m\^2 by vein on day 1.
Study NCT00501410 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: 85 mg/m\^2 by vein on day 1.
Study NCT01031511 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioural Therapy
Description: 16 weekly sessions of 1.5 hrs in small groups of 3-4 children conducted by 2 therapists
Study NCT01031511 — intervention group
Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: Social Recreational
Description: 16 weekly sessions of 1.5 hrs in small groups of 3-4 children, conducted by 2 therapists
Study NCT04167319 — intervention group
Intervention type: OTHER
Intervention: QST and PRO measurements during treatment
Description: We will observe the natural course of CIPN using multiple measurements
Study NCT01220466 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: STAR S4IR LASIK with iDesign Aberrometer
Description: CustomVue LASIK targeted for emmetropia
Study NCT00912743 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: olaparib
Description: 400 mg po bid continuously
Study NCT00003611 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: acitretin
Study NCT00003611 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study NCT03563131 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Persona® total knee arthroplasty
Description: Insertion of the cemented or uncemented Persona® total knee arthroplasty
Study NCT01195012 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Helping HAND (Healthy Nutrition and Activity Directions)
Description: 6-month behavioral intervention targeting 5-8 year old children and their parents to improve the child's lifestyle behaviors to improve their weight status. The families met monthly with trained Health Advisors for individual sessions in the pediatric clinic with phone calls in between visits to check on progress.
Study NCT03259464 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 685509
Description: 3 sequential dose groups
Study NCT03259464 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 3 sequential dose groups
Study NCT01470248 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arsenic Trioxide
Description: Drug will be given as a loading dose of 0.32mg/kg/day for 4 days in Week 1, followed by 0.25mg/kg/day twice per week for 5 weeks, followed by 2 weeks of rest, at which time response assessment will be performed. Patients will be restaged prior to the beginning of a new cycle, every 2 months on average. Maximum of 6 cycles of therapy will be administered in the absence of tumor progression or excessive side effects
Study NCT03137238 — intervention group
Intervention type: OTHER
Intervention: Investigation of self-perception in Parkinson's disease
Description: There is no therapeutic intervention.
Study NCT01553422 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fluid therapy (Saline Normal)
Description: Saline Normal 1 Lit. during 30 minutes
Study NCT01553422 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fluid therapy (Saline Normal)
Description: saline Normal 1 lit during 30 minutes
Study NCT02215369 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VenaCure EVLT 400 µm fiber Procedure Kit
Description: The study intervention will be conducted according to the DFU included with the VenaCure EVLT 400 µm fiber Procedure Kit.
Study NCT04297748 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: 89Zirconium-M7824
Description: PET imaging agent
Study NCT04297748 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M7824
Description: Bifunctional fusion protein intended to block PD-L1 and neutralize TGFbeta simultaneously.
Study NCT00457197 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Inactive ingredient matching the active medication in appearance.
Study NCT00457197 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Quetiapine
Description: Quetiapine is an atypical antipsychotic approved for the treatment of schizophrenia, bipolar disorder, and in the XR version along with an SSRI to treat major depressive disorder.
Study NCT00605631 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cardiac pacing using any Guidant/Boston Scientific Implantable ICD or CRT-D System and any Guidant/Boston Scientific Intracardiac Lead System
Description: No specific device model is required - any FDA-approved, market-released Guidant/Boston Scientific implantable ICD or CRT-D system and any FDA-approved, market-released Guidant/Boston Scientific intracardiac lead system may be implanted as part of MENDMI.
Study NCT00605631 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cardiac pacing using any Guidant/Boston Scientific Implantable ICD or CRT-D System and any Guidant/Boston Scientific Intracardiac Lead System
Description: No specific device model is required - any FDA-approved, market-released Guidant/Boston Scientific implantable ICD or CRT-D system and any FDA-approved, market-released Guidant/Boston Scientific intracardiac lead system may be implanted as part of MENDMI.
Study NCT00605631 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Cardiac pacing using any Guidant/Boston Scientific Implantable ICD or CRT-D System and any Guidant/Boston Scientific Intracardiac Lead System
Description: No specific device model is required - any FDA-approved, market-released Guidant/Boston Scientific implantable ICD or CRT-D system and any FDA-approved, market-released Guidant/Boston Scientific intracardiac lead system may be implanted as part of MENDMI.
Study NCT01549587 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.243% sodium fluoride
Description: dentifrice: brush thoroughly twice daily
Study NCT01549587 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: toothbrush
Description: brush thoroughly twice daily
Study NCT01549587 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: dental floss
Description: floss the whole mouth once daily
Study NCT01549587 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.454% stannous fluoride
Description: dentifrice: twice daily brush thoroughly for 2 minutes
Study NCT01549587 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: toothbrush
Description: twice daily brush thoroughly for 2 minutes
Study NCT01549587 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.07% Cetylpyridinium chloride
Description: mouth rinse: rinse with 20 mL of mouth rinse for 30 seconds twice daily
Study NCT01549587 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: dental floss
Description: floss the whole mouth once daily
Study NCT02678065 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: InPact Admiral DEB
Study NCT01195012 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Helping HAND (Healthy Nutrition and Activity Directions)
Description: 6-month behavioral intervention targeting 5-8 year old children and their parents to improve the child's lifestyle behaviors to improve their weight status. The families met monthly with trained Health Advisors for individual sessions in the pediatric clinic with phone calls in between visits to check on progress.
Study NCT02224729 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine hydrochloride
Description: Given IV
Study NCT02224729 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Given SC
Study NCT02224729 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given PO
Study NCT01362140 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darbepoetin alfa
Description: Administered by subcutaneous injection every 3 weeks
Study NCT01362140 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered by subcutaneous injection every 3 weeks
Study NCT02774057 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Captafer®
Description: 2 pills daily. Contains~* Vitamin C, known for its property to facilitate iron absorption by reducing iron to the reduced ferrous state necessary for uptake;~* Vitamin E, an antioxidant, along with vitamin C it protects Fe++;~* Folic acid, necessary to prevent megaloblastic anemia and abnormalities in the fetal nervous system, vital during pregnancy;~* Zinc and Copper which act in different mitochondrial cytochromes-dependent systems and contribute to the use of iron by the biological systems
Study NCT00034281 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-165
Description: Starting dose of TAK-165 10 mg, tablets, orally, once daily with dose escalation to tolerability for 56 days.
Study NCT01508091 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: energy restricted mediterranean-type diet
Description: Prescription of diet 25 % lower than actual total energy expenditure in overweight or moderately obese premenopausal women
Study NCT01508091 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 25 % calorie restriction
Description: 25 % calorie restriction respect total energy expenditure
Study NCT01068678 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin degludec
Description: Injected subcutaneously (under the skin) three times weekly. Dose was individually adjusted.
Study NCT01068678 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin glargine
Description: Injected subcutaneously (under the skin) once daily. Dose was individually adjusted.
Study NCT03314792 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tapentadol
Description: * Palexia depot 50 mg® (tapentadol depot 50 mg): Administered by the patient as oral premedication 1 hour before scheduled start of surgery. Palexia depot is repeated once after 12 hours.~* Palexia 50 mg® (tapentadol 50 mg): Administered as oral rescue medicine. First possible administration in postoperative ward when the patient is awake and available for oral medication. Maximum 4 tablets/24-hour study period. Minimum 1 hour 15 minutes between tablets. The patient is instructed to take 1 tablet if pain is increasing and the minimum period since last tablet is exceeded.
Study NCT03314792 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxycodone
Description: * OxyContin 10 mg® (oxycodone extended-release 10 mg): Administered by the patient as oral premedication 1 hour before scheduled start of surgery. OxyContin is repeated once after 12 hours.~* OxyNorm 10 mg® (oxycodone immediate-release 10 mg): Administered as oral rescue medicine. First possible administration in postoperative ward when the patient is awake and available for oral medication. Maximum 4 capsules/24-hour study period. Minimum 1 hour 15 minutes between capsules. The patient is instructed to take 1 tablet if pain is increasing and the minimum period since last tablet is exceeded.